DNMT3A and acute myeloid leukemia: These cases, when achieve long-term molecular (MRD-negative) remission, are likely to be cured, even though the persistence of detectable copies of the DNMT3A mutant (indicating persistent clonal hemopoiesis) may expose them to a low risk of developing a second AML [4].